Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kise Mer (Proto Oncogene c Mer or Receptor Tyrosine Kise MerTK or MERTK or EC 2.7.10.1) - Overview
Tyrosine Protein Kise Mer (Proto Oncogene c Mer or Receptor Tyrosine Kise MerTK or MERTK or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kise Mer (Proto Oncogene c Mer or Receptor Tyrosine Kise MerTK or MERTK or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kise Mer (Proto Oncogene c Mer or Receptor Tyrosine Kise MerTK or MERTK or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Tyrosine Protein Kise Mer (Proto Oncogene c Mer or Receptor Tyrosine Kise MerTK or MERTK or EC 2.7.10.1) - Drug Profiles
Tyrosine Protein Kise Mer (Proto Oncogene c Mer or Receptor Tyrosine Kise MerTK or MERTK or EC 2.7.10.1) - Dormant Products
Tyrosine Protein Kise Mer (Proto Oncogene c Mer or Receptor Tyrosine Kise MerTK or MERTK or EC 2.7.10.1) - Discontinued Products
Tyrosine Protein Kise Mer (Proto Oncogene c Mer or Receptor Tyrosine Kise MerTK or MERTK or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Dec 15, 2021: Exelixis announces initiation of phase 1b trial evaluating Xl092 in combition with immuno-oncology therapies in patients with advanced solid tumors
Sep 20, 2021: Mirati Therapeutics announces long-term survival results from an exploratory alysis of sitravatinib plus nivolumab in patients with non-squamous non-small cell lung cancer who are resistant to checkpoint inhibitors
Apr 11, 2021: BeiGene presents clinical data on Sitravatinib in combition with Tislelizumab at the AACR Annual Meeting 2021
Mar 18, 2021: Exelixis announces clinical trial collaboration and supply agreement with Merck and Pfizer to evaluate XL092 and Avelumab in various forms of locally advanced or metastatic urothelial carcinoma
Mar 10, 2021: BeiGene announces presentation of clinical data on Sitravatinib in combition with tislelizumab at the AACR Annual Meeting 2021
Jan 26, 2021: Qurient enrolls first patient in Q702 U.S. phase 1 study
Oct 26, 2020: Exelixis announces first patient enrolled in Phase 1 trial cohort evaluating XL092 in combition with Atezolizumab in patients with advanced solid tumors
Oct 09, 2020: Exelixis to present the preclinical profile and initial clinical pharmacokinetics of XL092, its next-generation oral tyrosine kise inhibitor
Sep 18, 2020: Mirati Therapeutics presents phase 2 data on sitravatinib in combition with nivolumab in urothelial cancer At ESMO Virtual Congress
Jun 22, 2020: RGENIX presents results from preclinical safety and efficacy studies of RGX-019 at the 2020 AACR Annual Meeting
May 26, 2020: Qurient announces U.S. FDA clearance of IND application for Q702, a novel cancer immunotherapy
Feb 15, 2020: Mirati Therapeutics announces initial data in Rel Cell Carcinoma from ongoing investigator sponsored clinical trial Of Sitravatinib in combition With Nivolumab at The 2020 ASCO Genitouriry Cancers Syposium
Dec 13, 2019: Sitravatinib plus Tislelizumab show promise in platinum-resistant advanced ovarian cancer
Nov 09, 2019: Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combition With Nivolumab At The SITC 34th Annual Meeting
Oct 23, 2019: Mirati Therapeutics announces presentation of interim phase 2 Sitravatinib data In Urothelial Carcinoma and Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Antengene Corp Ltd, 2022
Pipeline by Aucentra Therapeutics Pty Ltd, 2022
Pipeline by Celldex Therapeutics Inc, 2022
Pipeline by Celon Pharma SA, 2022
Pipeline by Dong-A Socio Holdings Co Ltd, 2022
Pipeline by Eli Lilly and Co, 2022
Pipeline by Exelixis Inc, 2022
Pipeline by F. Hoffmann-La Roche Ltd, 2022
Pipeline by Halia Therapeutics Inc, 2022
Pipeline by HEC Pharma Co Ltd, 2022
Pipeline by Incyte Corp, 2022
Pipeline by Inspirna Inc, 2022
Pipeline by Mediolanum farmaceutici SpA, 2022
Pipeline by Meryx Inc, 2022
Pipeline by Mirati Therapeutics Inc, 2022
Pipeline by Ono Pharmaceutical Co Ltd, 2022
Pipeline by Pfizer Inc, 2022
Pipeline by Qurient Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022